BACKGROUND: Systemic inflammation after coronary intervention identifies patients at increased risk of subsequent cardiac events. Cardiac events are less frequent after use of drug eluting stents (DES) compared with bare metal stents (BMS). Thus, we sought to determine whether attenuation of the systemic inflammatory response was contributing to the improved outcomes. METHODS: A prospective registry was initiated in late 2003. Peripheral venous blood samples from 75 patients undergoing percutaneous coronary intervention (PCI) were obtained before PCI, and both 1 hour and 24 hours after stenting. The concentrations of C-reactive protein (CRP), interleukin-6 (IL-6) and interleukin-1 receptor antagonist (IL1-Ra) were determined by ELISA. Eleven patients were excluded from the analysis because they had both DES and BMS. RESULTS: Patients treated with BMS (n=29) compared with DES (n=34) had a higher incidence of marker-positive acute coronary syndromes (40% vs. 17%, p=0.06), vein graft PCI (p=0.02) and a larger final balloon diameter (p=0.04). Consistent with the lower baseline clinical risk, pre-PCI concentrations of cytokines were lower in the DES group (p=0.04 for IL-6 and p=0.08 for CRP). Comparable and significant increases in CRP, IL-6 and IL1-Ra were evident 24 hours after PCI in patients treated with either DES or BMS. After controlling for baseline levels of CRP, there remained a similar and robust (300%) relative increase in CRP for both DES and BMS patients. CONCLUSIONS: The inflammatory response to PCI appears similar in those treated with DES and BMS. Accordingly, the reduction in restenosis after DES is likely not mediated by attenuation of the systemic markers CRP, IL-1Ra, or IL-6.
BACKGROUND: Systemic inflammation after coronary intervention identifies patients at increased risk of subsequent cardiac events. Cardiac events are less frequent after use of drug eluting stents (DES) compared with bare metal stents (BMS). Thus, we sought to determine whether attenuation of the systemic inflammatory response was contributing to the improved outcomes. METHODS: A prospective registry was initiated in late 2003. Peripheral venous blood samples from 75 patients undergoing percutaneous coronary intervention (PCI) were obtained before PCI, and both 1 hour and 24 hours after stenting. The concentrations of C-reactive protein (CRP), interleukin-6 (IL-6) and interleukin-1 receptor antagonist (IL1-Ra) were determined by ELISA. Eleven patients were excluded from the analysis because they had both DES and BMS. RESULTS:Patients treated with BMS (n=29) compared with DES (n=34) had a higher incidence of marker-positive acute coronary syndromes (40% vs. 17%, p=0.06), vein graft PCI (p=0.02) and a larger final balloon diameter (p=0.04). Consistent with the lower baseline clinical risk, pre-PCI concentrations of cytokines were lower in the DES group (p=0.04 for IL-6 and p=0.08 for CRP). Comparable and significant increases in CRP, IL-6 and IL1-Ra were evident 24 hours after PCI in patients treated with either DES or BMS. After controlling for baseline levels of CRP, there remained a similar and robust (300%) relative increase in CRP for both DES and BMS patients. CONCLUSIONS: The inflammatory response to PCI appears similar in those treated with DES and BMS. Accordingly, the reduction in restenosis after DES is likely not mediated by attenuation of the systemic markers CRP, IL-1Ra, or IL-6.
Authors: Robert S Schwartz; Elazer R Edelman; Andrew Carter; Nicolas Chronos; Campbell Rogers; Keith A Robinson; Ron Waksman; Judah Weinberger; Robert L Wilensky; Donald N Jensen; Bram D Zuckerman; Renu Virmani Journal: Circulation Date: 2002-10-01 Impact factor: 29.690
Authors: A M Lincoff; D J Kereiakes; M A Mascelli; L I Deckelbaum; E S Barnathan; K K Patel; B Frederick; M T Nakada; E J Topol Journal: Circulation Date: 2001-07-10 Impact factor: 29.690
Authors: Gregg W Stone; Stephen G Ellis; David A Cox; James Hermiller; Charles O'Shaughnessy; James Tift Mann; Mark Turco; Ronald Caputo; Patrick Bergin; Joel Greenberg; Jeffrey J Popma; Mary E Russell Journal: N Engl J Med Date: 2004-01-15 Impact factor: 91.245
Authors: J Eduardo Sousa; Marco A Costa; Amanda G M R Sousa; Alexandre C Abizaid; Ana C Seixas; Andrea S Abizaid; Fausto Feres; Luiz A Mattos; Robert Falotico; Judith Jaeger; Jeffrey J Popma; Patrick W Serruys Journal: Circulation Date: 2003-01-28 Impact factor: 29.690
Authors: Jeffrey W Moses; Martin B Leon; Jeffrey J Popma; Peter J Fitzgerald; David R Holmes; Charles O'Shaughnessy; Ronald P Caputo; Dean J Kereiakes; David O Williams; Paul S Teirstein; Judith L Jaeger; Richard E Kuntz Journal: N Engl J Med Date: 2003-10-02 Impact factor: 91.245
Authors: Prospero B Gogo; David J Schneider; Edward F Terrien; Burton E Sobel; Harold L Dauerman Journal: J Thromb Thrombolysis Date: 2006-12 Impact factor: 2.300
Authors: Grant C Alexander; Jeremy B Vines; Patrick Hwang; Teayoun Kim; Jeong-a Kim; Brigitta C Brott; Young-Sup Yoon; Ho-Wook Jun Journal: ACS Appl Mater Interfaces Date: 2016-02-17 Impact factor: 9.229
Authors: Lorraine Frazier; William K Vaughn; James T Willerson; Christie M Ballantyne; Eric Boerwinkle Journal: Biol Res Nurs Date: 2009-02-26 Impact factor: 2.522